The emergence of multireceptor agonists is building on the success of GLP-1 receptor agonists, which have transformed care for type 2 diabetes and obesity by enabling effective glycaemic control, weight management, and improved cardiovascular and kidney outcomes.
Researchers are now exploring whether modulating additional nutrient-stimulated hormone receptors can produce even greater efficacy, broader metabolic benefits, or better tolerability. This shift reflects a growing interest in unimolecular drugs that engage multiple hormone pathways simultaneously.
Data from The Lancet commentary highlight that tirzepatide—a dual agonist of GLP-1 and gastric inhibitory polypeptide (GIP) receptors—induces greater improvements in glycated haemoglobin (HbA1c) and weight than semaglutide at a 1 mg dose in people with type 2 diabetes. Tirzepatide is available at 5 mg, 10 mg, or 15 mg doses.
These findings suggest that multireceptor modulation could become a new standard for metabolic disease treatment, potentially offering patients more effective options. However, the question remains whether increasing the number of targets reliably delivers better value or simply adds complexity and cost.
Some experts caution that more targets do not always mean better outcomes; tolerability and long-term safety must be carefully weighed. The commentary underscores the need for further trials comparing multireceptor agents against established therapies.